NIH Approves Strategic Vision to Transform National Library of Medicine
National Institutes of Health Director Francis S. Collins, has approved a federal report that lays out the long-term scientific vision for the NIH’s National Library of Medicine (NLM), the world’s largest biomedical library.
This vision, presented at the 110th meeting of the Advisory Committee to the Director (ACD), calls for NIH to position the NLM as a unifying force in biomedicine that promotes and accelerates knowledge generation, dissemination and understanding in the United States and internationally. The report also cites the need to make NLM the epicenter for biomedical data science, not just at NIH, but across the biomedical research enterprise. In addition, the report recommends dramatically expanding NLM’s activities to include research conducted beyond NIH’s walls to funded institutions, enabling it to have a greater and wider impact on data science than ever before. NIH plans to work with Congress to implement the necessary infrastructure changes to move this vision forward.
“The pace of change in biomedical data science is moving at lightning speed with the increasing use of big data and the melding of many diverse data types,” said Dr Collins. “It is critical that NIH pave the path forward for data science, and this move will enable researchers, medical practitioners and many others to use the wealth of vast knowledge and data available to them through the NLM.”
To capitalize on the emerging opportunities in data science, Dr Collins tasked a working group of his ACD to lay out a strategic vision for the NLM to maintain its global leadership in biomedical and health information. Comprised of experts in the fields of biomedical research, bioinformatics, library sciences, publishing, and patient care, the working group assessed the current mission, organization and programmatic priorities of the NLM. The group presented its recommendations for a strategic vision to the ACD, and it was subsequently unanimously endorsed. In summary, the ACD envisioned NLM to be a modernized conceptualization of a library and formulated a series of recommendations to guide its future:
• Continually evolve to remain a leader in assimilating and disseminating accessible and authoritative biomedical research findings and trusted health information to the public, healthcare professionals, and researchers worldwide.
• Lead efforts to support and catalyze open science, data sharing, and research reproducibility, striving to promote the concept that biomedical information and its transparent analysis are public goods.
• Be the intellectual and programmatic epicenter for data science at NIH, including becoming the center of intellectual and programmatic activities in biomedical data science, and stimulate its advancement throughout biomedical research and application.
• Strengthen its role in fostering the future generation of professionals in biomedical informatics, data science, library sciences, and related disciplines through sustained and focused training efforts.
• Maintain, preserve, and make accessible the nation’s historical efforts in advancing biomedical research and medicine, thereby ensuring that this legacy is both safe and accessible for long-term use.
• Have new NLM leadership evaluate what talent, resources, and organizational structures are required to ensure NLM can fully achieve its mission and best allocate its resources.
Dr Collins accepted the ACD recommendations in full, but acknowledged that NIH will need to consider the requirements and infrastructure implications for centering NIH’s biomedical data science activities within the NLM. In addition, NIH has launched a nationwide search for the director of the NLM to replace Donald Lindberg, who served as the NLM director for more than 30 years and retired in March 2015.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance